Dynavax Technologies Corp.
(NASDAQ : DVAX)

( )
DVAX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.27%176.780.0%$746.14m
AMGNAmgen, Inc. 1.08%251.081.5%$612.30m
VRTXVertex Pharmaceuticals, Inc. 3.74%305.531.9%$437.49m
GILDGilead Sciences, Inc. 5.16%66.211.0%$435.11m
REGNRegeneron Pharmaceuticals, Inc. 2.32%643.292.6%$372.05m
ILMNIllumina, Inc. 8.77%226.593.3%$330.40m
SNSSSunesis Pharmaceuticals, Inc. 5.74%4.420.7%$308.97m
NVAXNovavax, Inc. 2.00%42.3075.7%$284.25m
BIIBBiogen, Inc. 0.63%222.381.8%$205.32m
BNTXBioNTech SE 1.33%162.480.0%$158.03m
GOVXGeoVax Labs, Inc. 1.59%2.550.0%$140.51m
BMRNBioMarin Pharmaceutical, Inc. 1.97%96.944.2%$104.96m
CRSPCRISPR Therapeutics AG 1.88%80.140.6%$104.75m
PACBPacific Biosciences of California, Inc. -4.89%8.366.2%$98.27m
MRTXMirati Therapeutics, Inc. -0.06%86.321.6%$96.84m

Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.